IND In As Little As 6 Months: Now Beyond mAbs - Accelerating Bispecifics, Fc-Fusions And High-Concentration Biologics To The Clinic

As pressure to reach critical development milestones faster continues to grow, sponsors are seeking new ways to accelerate biologics programs without compromising product quality, manufacturability, or long-term scalability.

In this webinar, Lonza introduces newly expanded accelerated DNA-to-IND pathways designed to support a broader range of biologic modalities, including monoclonal antibodies, bispecifics, Fc-fusions, and high-concentration biologics. Drawing on technical data, case studies, and practical development experience, the session also explores how advances in expression technologies, integrated CMC strategies, and streamlined execution can help shorten development timelines while supporting robust program progression.

Viewers will learn how to select an accelerated pathway based on the characteristics and development goals of their molecule, understand the scientific and operational enablers behind accelerated timelines, and evaluate how early development decisions can influence both IND readiness and long-term program success.